Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00143871 · ClinicalTrials.gov registry record · Phase 2
Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT00143871 is a Phase 2 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 35 participants.
The verdict
NCT00143871, a Phase 2 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
This study is being conducted to determine the safety, side effects, and response to a combination of an established high-dose chemotherapy regimen, plus the addition of Rituximab (which is a form of immunotherapy).
Interventions
- DRUG Rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2001-04 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00143871
The ClinicalTrials.gov registry entry for NCT00143871 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rituximab is the first listed.
NCT00143871 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00143871 about?
NCT00143871 is a clinical study titled "Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma". This study is being conducted to determine the safety, side effects, and response to a combination of an established high-dose chemotherapy regimen, plus the addition of Rituximab (which is a form of immunotherapy).
What is the current status of trial NCT00143871?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2001-04. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00143871?
The interventions under investigation include: Rituximab (DRUG).
Who is sponsoring clinical trial NCT00143871?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.